Target-Specific Assays Archives

CDK4/6 Inhibitor Resistant Breast Cancer Models

Leverage our extensive panel of CDK4/6 inhibitor resistant breast cancer models, including: In vitro induced Palbociclib resistant MCF-7 cell line...

Ligand Finding and Chemistry Workflows for Targeted Protein Degradation

This webinar will focus on aspects related to PROTAC discovery and chemistry workflows, such as ligand finding strategies, synthesis optimization,...

Biological Characterization and Development Workflows for Targeted Protein Degradation

This webinar will focus on PROTAC biology workflows, such as in vitro screening assays, in vivo testing, and optimization of...

Discovery Newsletter November 2022

How Does It Work? | Antibody Drug Conjugates

In this week’s installment of our “How Does It Work?” video series, we explore Antibody Drug Conjugates. Monoclonal antibodies are...

How Does It Work? | Peptibodies

#Research has explored the ways to extend the half-life of peptide drugs. One innovative way to achieve this is by...

WuXi AppTec Oligonucleotide Biology Platform

We offer a wide range of oligonucleotide services, including: Sequence design Knockdown effect in cell lines and primary cells Splicing...

Pain Discovery Assays & In Vivo Models

WuXi AppTec offers a comprehensive platform to evaluate lead candidates targeting various types of pain, including inflammatory, neuropathic, and fibromyalgia-like...

OncoWuXi Newsletter: June 2022

WuXi AppTec xenograft and syngeneic tumor models in rats and CD47-related in vitro assay platform

Knowledge Library